Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 22020439
Uribesalgo I, et al. (2011) E-box-independent regulation of transcription and differentiation by MYC. Nat Cell Biol 13, 1443-9 22020439
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T358-p - Myc (human)
Modsite: EENVkRRtHNVLERQ SwissProt Entrez-Gene
Orthologous residues
Myc (human): T358‑p, Myc iso2 (human): T373‑p, Myc (mouse): T358‑p, Myc (rat): T358‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PAK2 (human) pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, phospho-antibody, transfection of wild-type enzyme, siRNA inhibition of enzyme
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  carcinogenesis, inhibited, cell differentiation, induced, transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Induces

S373-p - Myc (human)
Modsite: RRNELkRsFFALRDQ SwissProt Entrez-Gene
Orthologous residues
Myc (human): S373‑p, Myc iso2 (human): S388‑p, Myc (mouse): S373‑p, Myc (rat): S373‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HL60 (myeloid), NB-4 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE PAK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PAK2 (human) pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, phospho-antibody, transfection of wild-type enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
retinoic_acid increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  carcinogenesis, inhibited, cell differentiation, induced, transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Induces

T400-p - Myc (human)
Modsite: VVILKkAtAYILsVQ SwissProt Entrez-Gene
Orthologous residues
Myc (human): T400‑p, Myc iso2 (human): T415‑p, Myc (mouse): T400‑p, Myc (rat): T400‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PAK2 (human) pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, phospho-antibody, transfection of wild-type enzyme, siRNA inhibition of enzyme
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  carcinogenesis, inhibited, cell differentiation, induced, transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Induces